The Danish Cardiovascular Screening Trial (DANCAVAS): Study protocol for a randomized controlled trial

Trials

Volumn 16, Issue 1, 2015, Pages

  Diederichsen, Axel Cosmus Pyndt ^a   Rasmussen, Lars Melholt ^a   Søgaard, Rikke ^b   Lambrechtsen, Jess ^a   Steffensen, Flemming Hald ^c   Frost, Lars ^d   Egstrup, Kenneth ^a   Urbonaviciene, Grazina ^d   Busk, Martin ^c   Olsen, Michael Hecht ^a   Mickley, Hans ^a   Hallas, Jesper ^e   Lindholt, Jes Sanddal ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c LILLEBAELT HOSPITAL   (Denmark)

^d SILKEBORG REGIONAL HOSPITAL   (Denmark)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Aortic aneurysm; Atrial fibrillation; Benefit; Cardiovascular prevention; Coronary calcium score; Cost effectiveness; Peripheral arterial disease; Public health; Screening

Indexed keywords

CHOLESTEROL; GLUCOSE; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ADULT; AGE DISTRIBUTION; AGED; ANKLE BRACHIAL INDEX; AORTA ANEURYSM; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; COST EFFECTIVENESS ANALYSIS; DANISH CITIZEN; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH PROGRAM; HEART RHYTHM; HUMAN; HYPERTENSION; MALE; MASS SCREENING; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PILOT STUDY; POPULATION RESEARCH; PREVENTIVE MEDICINE; PROGRAM FEASIBILITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL RATE; AGE; ALGORITHM; ANALYSIS; BLOOD; BLOOD ANALYSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ANGIOGRAPHY; COST BENEFIT ANALYSIS; DENMARK; ECONOMICS; HEART RATE; METHODOLOGY; MORTALITY; MULTICENTER STUDY; PREDICTIVE VALUE; PREVENTIVE HEALTH SERVICE; PROCEDURES; PROGNOSIS; REGISTER; RISK FACTOR; SEX DIFFERENCE; TELEMETRY; TIME FACTOR; X-RAY COMPUTED TOMOGRAPHY;

AGE FACTORS; AGED; ALGORITHMS; ANKLE BRACHIAL INDEX; BIOMARKERS; BLOOD CHEMICAL ANALYSIS; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; CLINICAL PROTOCOLS; CORONARY ANGIOGRAPHY; COST-BENEFIT ANALYSIS; DENMARK; HEALTH CARE COSTS; HEART RATE; HUMANS; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PREVENTIVE HEALTH SERVICES; PROGNOSIS; REGISTRIES; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TELEMETRY; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84949213358     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-015-1082-6     Document Type: Article

References (44)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18-209.
2. Hjertestatistik 2013. http://www.hjerteforeningen.dk/film_og_boeger/udgivelser/hjertestatistik/.
3. Sillesen H, Falk E. Why not screen for subclinical atherosclerosis? Lancet. 2011;378(9792):645-6.
4. Polonsky TS, Greenland P. CVD screening in low-risk, asymptomatic adults: clinical trials needed. Nat Rev Cardiol. 2012;9(10):599-604.
5. Lindholt JS, Sorensen J, Sogaard R, Henneberg EW. Long-term benefit and cost-effectiveness analysis of screening for abdominal aortic aneurysms from a randomized controlled trial. Br J Surg. 2010;97(6):826-34.
6. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet. 2012;3.
7. Krogsboll LT, Jorgensen KJ, Gronhoj LC, Gotzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev. 2012;10:CD009009.
8. Perk J, De BG, Gohlke H, Graham I, Reiner Z, Verschuren M et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2012;33(13):1635-701.
9. Singh GM, Danaei G, Farzadfar F, Stevens GA, Woodward M, Wormser D, et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS One. 2013;8(7), e65174.
10. Diederichsen AC, Sand NP, Norgaard B, Lambrechtsen J, Jensen JM, Munkholm H, et al. Discrepancy between coronary artery calcium score and HeartScore in middle-aged Danes: the DanRisk study. Eur J Prev Cardiol. 2012;19(3):558-64.
11. Erbel R, Mohlenkamp S, Moebus S, Heinz Nixdorf Recall Study Investigative Group. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol. 2010;56(17):1397-406.
12. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA. 2010;303(16):1610-6.
13. Folsom AR, Kronmal RA, Detrano RC, O'Leary DH, Bild DE, Bluemke DA, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med. 2008;168(12):1333-9.
14. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O'Leary D, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308(8):788-95.
15. Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol. 2005;46(1):166-72.
16. Houslay ES, Cowell SJ, Prescott RJ, Reid J, Burton J, Northridge DB, et al. Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial. Heart. 2006;92(9):1207-12.
17. Sogaard R, Laustsen J, Lindholt JS. Cost effectiveness of abdominal aortic aneurysm screening and rescreening in men in a modern context: evaluation of a hypothetical cohort using a decision analytical model. BMJ. 2012;345, e4276.
18. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381-6.
19. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1-75.
20. McDermott MM. The magnitude of the problem of peripheral arterial disease: epidemiology and clinical significance. Cleve Clin J Med. 2006;73 Suppl 4:S2-7.
21. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: WHO; 1968.
22. Dupont WD, Plummer Jr WD. Power and sample size calculations for studies involving linear regression. Control Clin Trials. 1998;19(6):589-601.
23. Moll FL, Powell JT, Fraedrich G, Verzini F, Haulon S, Waltham M, et al. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. Eur J Vasc Endovasc Surg. 2011;41 Suppl 1:S1-58.
24. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219.
25. Authors/Task Force Members, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035-87.
26. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39(7 Suppl):30-3.
27. Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health. 2011;39(7 Suppl):26-9.
28. Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(7 Suppl):22-5.
29. Krarup LH, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology. 2007;28(3):150-4.
30. Nickelsen TN. Data validity and coverage in the Danish National Health Registry. A literature review. Ugeskr Laeger. 2001;164(1):33-7.
31. Nielsen HW, Tuchsen F, Jensen MV. Validity of the diagnosis "essential hypertension" in the National Patient Registry. Ugeskr Laeger. 1996;158(2):163-7.
32. Madsen M, Balling H, Eriksen LS. The validity of the diagnosis of acute myocardial infarction in 2 registries: the Heart Registry compared to the National Patient Registry. Ugeskr Laeger. 1990;152(5):308-14.
33. Petrou S, Gray A. Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. BMJ. 2011;342:d1548.
34. Sorensen J, Davidsen M, Gudex C, Pedersen KM, Bronnum-Hansen H. Danish EQ-5D population norms. Scand J Public Health. 2009;37(5):467-74.
35. Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ. 2011;342:d1766.
36. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res. 2007;168(1):1-64.
37. Einstein AJ, Knuuti J. Cardiac imaging: does radiation matter? Eur Heart J. 2012;33(5):573-8.
38. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-42.
39. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-60.
40. Lindholt JS, Juul S, Henneberg EW. High-risk and low-risk screening for abdominal aortic aneurysm both reduce aneurysm-related mortality. A stratified analysis from a single-centre randomised screening trial. Eur J Vasc Endovasc Surg. 2007;34(1):53-8.
41. Lindholt JS. Relatively high pulmonary and cardiovascular mortality rates in screening-detected aneurysmal patients without previous hospital admissions. Eur J Vasc Endovasc Surg. 2007;33(1):94-9.
42. Lindholt JS, Henneberg EW, Fasting H, Juul S. Mass or high-risk screening for abdominal aortic aneurysm. Br J Surg. 1997;84(1):40-2.
43. Lindholt JS, Juul S, Fasting H, Henneberg EW. Screening for abdominal aortic aneurysms: single centre randomised controlled trial. BMJ. 2005;330(7494):750.
44. Grondal N, Sogaard R, Henneberg EW, Lindholt JS. The Viborg Vascular (VIVA) screening trial of 65-74 year old men in the central region of Denmark: study protocol. Trials. 2010;11:67.